newsfilter
← Latest News
GlobeNewswire·

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Received FDA feedback on Pre-IND Briefing Document reinforcing Company's intention to advance investigational new drug (IND) submission for CUE-401 to address unmet need in the treatment of autoimmune disease.